BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 19,300,000 shares, a growth of 12.7% from the December 31st total of 17,120,000 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio is currently 9.9 days. Approximately 13.1% of the shares of the company are short sold.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 27,389 shares of the business's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares of the company's stock, valued at $109,751,697.63. The trade was a 0.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian C. Stephenson sold 4,156 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the sale, the chief financial officer now directly owns 93,758 shares of the company's stock, valued at approximately $2,101,116.78. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,492,093 shares of company stock worth $122,029,004 in the last ninety days. Insiders own 24.66% of the company's stock.

Hedge Funds Weigh In On BridgeBio Pharma

Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of BridgeBio Pharma by 5.2% in the second quarter. Dimensional Fund Advisors LP now owns 73,230 shares of the company's stock valued at $1,855,000 after acquiring an additional 3,624 shares during the period. Marshall Wace LLP bought a new position in shares of BridgeBio Pharma during the second quarter worth approximately $781,000. Handelsbanken Fonder AB raised its position in shares of BridgeBio Pharma by 17.7% in the third quarter. Handelsbanken Fonder AB now owns 32,550 shares of the company's stock valued at $829,000 after buying an additional 4,900 shares in the last quarter. Diversified Trust Co boosted its stake in shares of BridgeBio Pharma by 3.0% in the third quarter. Diversified Trust Co now owns 36,772 shares of the company's stock valued at $936,000 after buying an additional 1,059 shares during the period. Finally, CWM LLC grew its position in BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company's stock worth $88,000 after buying an additional 1,964 shares in the last quarter. Institutional investors own 99.85% of the company's stock.

BridgeBio Pharma Stock Performance

BBIO traded up $0.46 on Wednesday, reaching $33.44. The company had a trading volume of 1,352,752 shares, compared to its average volume of 2,945,962. The stock has a market cap of $6.32 billion, a P/E ratio of -13.97 and a beta of 1.07. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $41.04. The company's fifty day moving average is $30.32 and its 200 day moving average is $27.27.

Analyst Upgrades and Downgrades

BBIO has been the subject of a number of recent research reports. Evercore ISI boosted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, December 23rd. HC Wainwright restated a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Monday, December 16th. Scotiabank lifted their price target on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a "sector outperform" rating in a research report on Monday, November 25th. Leerink Partners dropped their price target on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. Finally, Bank of America lifted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, November 25th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, BridgeBio Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $49.00.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.